These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32738068)

  • 41. [Prevention of posttransfusion graft-versus-host disease by leukocyte depletion filter].
    Handa M
    Nihon Rinsho; 1997 Sep; 55(9):2282-9. PubMed ID: 9301291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atypical, nonfatal, transfusion-associated, acute graft-versus-host disease in a patient with Hodgkin's disease.
    Held JL; Druker BJ; Kohn SR; Byrnes W; Margolis RJ
    J Am Acad Dermatol; 1992 Feb; 26(2 Pt 1):261-2. PubMed ID: 1552066
    [No Abstract]   [Full Text] [Related]  

  • 43. Advances in transfusion therapy.
    Beck SJ
    Clin Lab Sci; 1994; 7(4):225-31. PubMed ID: 10147432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transfusion-associated graft-versus-host disease, monoclonal gammopathy and PCR.
    Blundell EL; Pamphilon DH; Anderson NA; Slade RR; Burton PA; Martin A; Ray T; Bradley BA; Lawler M; Humphries P
    Br J Haematol; 1992 Nov; 82(3):622-3. PubMed ID: 1486045
    [No Abstract]   [Full Text] [Related]  

  • 45. Irradiated blood products to prevent graft-versus-host disease.
    Whiteley AB
    J Clin Oncol; 1992 Mar; 10(3):506. PubMed ID: 1740686
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of irradiated blood components: practice parameter.
    Przepiorka D; LeParc GF; Stovall MA; Werch J; Lichtiger B
    Am J Clin Pathol; 1996 Jul; 106(1):6-11. PubMed ID: 8701934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Chronic posttransfusion graft-vs-host disease in a patient with non-Hodgkin's lymphoma].
    García Gala JM; Ramírez Páyer A; Rayón C; Rodríguez Vicente P; Rosón C; Blanco C
    Sangre (Barc); 1993 Dec; 38(6):489-91. PubMed ID: 8171385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Post-transfusion graft vs host disease and its prevention].
    Stanković B
    Vojnosanit Pregl; 2000; 57(2):197-204. PubMed ID: 10934933
    [No Abstract]   [Full Text] [Related]  

  • 49. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components.
    Anderson K
    Transfusion; 2003 Dec; 43(12):1652-4. PubMed ID: 14641857
    [No Abstract]   [Full Text] [Related]  

  • 50. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors.
    Shivdasani RA; Haluska FG; Dock NL; Dover JS; Kineke EJ; Anderson KC
    N Engl J Med; 1993 Mar; 328(11):766-70. PubMed ID: 8437597
    [No Abstract]   [Full Text] [Related]  

  • 51. Demographics and appropriateness of cellular blood component irradiation practices: Ambispective analysis from a tertiary care center.
    Arjunan C; Khetan D; Singh V; Elhence P; Chaudhary RK; Kumar A
    Transfus Apher Sci; 2023 Jun; 62(3):103651. PubMed ID: 36774274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Prevention of graft-vs.-host disease.
    Woods WG
    Am J Pediatr Hematol Oncol; 1984; 6(3):283-6. PubMed ID: 6393792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical characteristics and evaluation of risk in the graft versus host reaction following transfusion].
    von Fliedner VE; Grob JP; Barrelet L
    Schweiz Med Wochenschr; 1983 Oct; 113(41):1521-3. PubMed ID: 6635642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfusion medicine 1994.
    Pineda A; Korbling M; Rock GA
    Rev Invest Clin; 1994 Apr; Suppl():101-15. PubMed ID: 7886293
    [No Abstract]   [Full Text] [Related]  

  • 55. [Transfusion related graft versus host disease. Indications for irradiated blood components].
    Muñiz-Díaz E; Martínez Valverde C; Sierra J; Madoz P
    Sangre (Barc); 1999 Dec; 44(6):483-8. PubMed ID: 10822764
    [No Abstract]   [Full Text] [Related]  

  • 56. Orthotopic small bowel transplantation in rats: pretreatment of the donor with the aim of ameliorating graft-versus-host disease.
    Saat RE; de Bruin RW; Heineman E; Marquet RL; Jeekel J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2892-3. PubMed ID: 2650393
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?
    Fast LD; Nevola M; Tavares J; Reddy HL; Goodrich RP; Marschner S
    Transfusion; 2013 Feb; 53(2):373-81. PubMed ID: 22612327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
    Cid J
    Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perspectives on transfusion-associated graft-versus-host disease.
    Jeter E
    Int J Artif Organs; 1994 Jan; 17(1):1-4. PubMed ID: 8188393
    [No Abstract]   [Full Text] [Related]  

  • 60. Transfusion associated graft versus host disease.
    Tipu HN; Ahmed TA; Khalilullah ; Ahmed S; Satti T; Ahmed P
    J Pak Med Assoc; 2008 Mar; 58(3):143-5. PubMed ID: 18517122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.